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The Genetic Sonogram
Comparing the Use of Likelihood Ratios Versus Logistic
Regression Coefficients for Down Syndrome Screening
Yan Zhong, MD, Ryan Longman, MD, Rachael Bradshaw, MS, Anthony O. Odibo, MD, MSCE

Article includes CME test

Objectives—The purpose of this study was to compare the screening efficiency for
Down syndrome using likelihood ratios versus logistic regression coefficients.
Methods—We conducted a retrospective study of women at increased risk for Down
syndrome referred for a second-trimester genetic sonogram. Likelihood ratios were calculated by multiplying the risk ratio from maternal serum screening by the likelihood ratios of sonographic markers. Logistic regression coefficients were calculated using a
formula derived from β coefficients generated from a multivariable logistic regression
model. The screening efficiency of both methods was tested in an independent population of patients. The McNemar test was used to compare the predictive ability of the
two methods.
Results—In the validation population, the use of likelihood ratios had an area under
the receiver operator characteristic curve of 0.90 for Down syndrome detection, whereas
the use of logistic regression coefficients had an area under the curve of 0.86. Adopting
a risk cutoff point of 1/270, the sensitivity of likelihood ratios was 77.4% (95% confidence interval [CI], 58.9%–90.4%) with a false-positive rate of 17.9% (95% CI, 15.0%–
21.1%), whereas the sensitivity of logistic regression coefficients was 93.5% (95% CI,
78.6%–99.2%) with a false-positive rate of 34.6% (95% CI, 30.9%–38.4%). There was
significant difference in screening efficiency for Down syndrome detection between the
two methods (exact McNemar χ2, P < .001 ).
Conclusions—With a slight reduction in the Down syndrome detection rate, the use of
the likelihood ratio approach was associated with a significantly lower false-positive rate
compared with the logistic regression approach.
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D

own syndrome is the most common cause of aneuploidy.
It is characterized by a combination of birth defects that include cognitive impairment, dysmorphic facial features, and
structural defects.1 Caring for children with Down syndrome can
place substantial emotional and financial strain on a family. Prenatal detection of fetuses affected with Down syndrome can prepare
the parents for the birth of an affected child or offer them the option of pregnancy termination. Second-trimester maternal serum
screening for Down syndrome is now part of routine prenatal care.2
In addition, the genetic sonogram in the second trimester provides
a noninvasive tool for identifying women whose pregnancies are at
increased risk for Down syndrome and who may be candidates for
invasive prenatal diagnosis.
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Both maternal serum screening and the genetic sonogram have limitations in their ability to detect Down syndrome. To improve the predictive ability, formulas based on
multivariable logistic regression analysis have been suggested.3 Although these formulas are reported to have high
sensitivity, the false-positive rates are also high. For example,
Vergani et al4 reported sensitivity of 83.3% with a falsepositive rate of 28.5%. Moreover, the complicated calculations of the formulas have limited their use in clinical practice.
On the other hand, physicians in clinical practice tend to use
a simpler method, which modifies the risk for Down syndrome by combining maternal serum screening results and
likelihood ratios based on sonographic markers.5–8
The aim of our study was to compare the performance
of likelihood ratios and logistic regression coefficients in a
cohort of women at increased risk for fetal Down syndrome based on maternal serum screening.

Materials and Methods
This was a retrospective cohort study of women at increased risk for Down syndrome referred for sonographic
and genetic evaluation at Washington University Medical
Center from 1991 through 2006 because of abnormal
second-trimester serum screening results. All referred
women seen between 15 and 22 weeks’ gestation were
evaluated with a genetic sonogram. Multiple pregnancies
and aneuploidy other than Down syndrome were excluded. Approval from the Institutional Review Board at
our center was obtained.
Serum analyte levels (α-fetoprotein, estriol, and βhuman chorionic gonadotropin and dimeric inhibin A after
1996) were converted to multiples of the median after adjusting for gestational age, ethnicity, preconceptional insulin use, and body mass index, and risk ratios for Down
syndrome were calculated after incorporating for maternal age. Sonographic examinations were performed by an
obstetric sonographer, and the images were reviewed by
maternal-fetal medicine specialist without prior knowledge
of the fetal karyotype. Sonographic assessment of Down
syndrome included the following sonographic soft markers: nuchal fold thickness, defined as 6 mm or greater based
on the mean of 3 measurements obtained in the standard
suboccipital plane from skull edge to skin edge; hyperechoic bowel, defined as bowel with echogenicity equal to
or greater than the adjacent pelvic bone; echogenic intracardiac focus, defined as punctuate intracardiac echogenic
areas within either or both of the cardiac ventricles with
echogenicity equal to that of bone; renal pyelectasis, defined as an anteroposterior diameter of the renal pelvis of
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4 mm or greater; extremity shortening, including humerus
or femur shortening; and any major structural abnormalities. Nasal bone evaluation was introduced into the sonographic assessment in 2005 and was not used for this
present study. Fetal karyotype information was obtained
from the results of cytogenetic examinations performed at
second-trimester amniocentesis or by postnatal testing
when the postnatal examination was suspicious for a chromosomal abnormality.
Two methods of adjusting the risk for Down syndrome were compared in the study: likelihood ratios
versus logistic regression coefficients derived for our population. The use of the likelihood ratios involved calculating the postsonographic risk for Down syndrome by
multiplying the risk ratio from maternal serum screening
with the likelihood ratios of sonographic markers seen during the sonographic evaluation. The likelihood ratios of the
sonographic markers were derived from a previous publication by Nicolaides (Table 1).7 For example, if the risk
ratio for Down syndrome based on maternal serum screening alone was 1/100 with the sonographically detected
presence of both nuchal fold thickness (positive likelihood
ratio, 53.05) and an echogenic intracardiac focus (positive
likelihood ratio, 6.41) but no other defects, then the final
risk ratio for Down syndrome calculated by the use of likelihood ratio was (1/100) × 53.05 × 6.41 × 0.68 × 0.62 ×
0.85 × 0.87 × 0.79 = 1/1.2 (Table 1).7 The use of logistic
regression involved calculating the risk ratio for Down syndrome by a formula derived from β coefficients for Down
syndrome generated from a multivariable logistic regression model. The model included the presence of sonographic markers described above. Data from 1990 through
2002 were used to generate the logistic regression formula,
whereas those from 2003 through 2006 were used to validate the model and in the comparison of the predictive
ability of the two methods. Patients were classified as test
positive or negative using a cutoff of 1/270, which is the
Table 1. Likelihood Ratios of Second-Trimester Sonographic Markers for Down Syndrome Used in This Study
Marker
Nuchal fold
Short humerus
Short femur
Hydronephrosis
Echogenic focus
Echogenic bowel
Major defect

Positive LR (95% CI)

Negative LR (95% CI)

53.05 (39.37–71.26)
22.76 (18.04–28.56)
7.94 (6.77–9.25)
6.77 (5.16–8.80)
6.41 (5.15–7.90)
21.17 (14.34–31.06)
32.96 (23.90–43.28)

0.67 (0.61–0.72)
0.68 (0.62–0.73)
0.62 (0.56–0.67)
0.85 (5.16–8.80)
0.75 (0.69–0.80)
0.87 (0.83–0.91)
0.79 (0.74–0.83)

Data reprinted with permission from Nicolaides.7 CI indicates confidence
interval; and LR, likelihood ratio.
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risk for Down syndrome for a 35-year-old woman that has
been used in several previously published studies. The sensitivity and false-positive rates were calculated by comparing the predicted results from the two methods with the
eventual diagnosis of Down syndrome. The McNemar test
and κ statistic were used to compare the predictive ability
of the two methods.
Descriptive statistics included means and SDs for continuous variables and frequency distributions for categorical variables. Comparisons between categorical variables
were tested using the χ2 test. Comparisons between continuous variables were performed using the Student t test
for normally distributed variables and the Wilcoxon ranksum test for variables that were not normally distributed.
A multivariable logistic regression model was developed
with confounders included in the model at P < .1 in the
univariate analyses and by their biological plausibility. Stata
version 10.0 software (StataCorp, College Station, TX)
was used for statistical analyses.

Results
The maternal characteristics of the population from 1990
through 2002 are shown in Table 2. In the cohort of 1834
women, 46 cases were affected by Down syndrome
(2.51%). Women with Down syndrome–affected fetuses
were older (35 ± 5.61 years) than women without Down
syndrome–affected fetuses (31 ± 5.73 years). There was
no difference in gestational age at examination between
the two groups. The mean risk of Down syndrome calculated by maternal serum screening alone in women with
Down syndrome–affected fetuses (1/79) was significantly
Table 2. Maternal Characteristics in the Population From 1990
Through 2002
Characteristic
Patients
Age, y
Gestational age, wk
Race
White
Black
Hispanic
Asian
Other
Median risk for Down
syndrome by maternal
serum screening

Down
Syndrome

Non–Down
Syndrome

46 (2.5)
35 ± 5.6
19 ± 1.9

1788 (97.5)
31 ± 5.7
19.1 ± 1.8

42 (91.3)
1 (2.2)
1 (2.2)
0 (0)
2 (4.4)

1379 (77.1)
312 (17.5)
14 (0.8)
46 (2.6)
37 (2.1)

1/79

1/155

P
<.001
.86
.03

.006

Data are number (percent) and mean ± SD. CI indicates confidence
interval; and LR, likelihood ratio.
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higher than that of women without Down syndrome–
affected fetuses (1/155).
The univariate comparison for the association between
sonographic markers and Down syndrome is displayed in
Table 3. Nuchal fold thickness (odds ratio, 30.9; 95% confidence interval [CI], 13.6–70.3) and the presence of any
major abnormality (odds ratio, 24.2; 95% CI, 12.0–48.9 )
showed the strongest association with Down syndrome. An
echogenic intracardiac focus, a renal pelvis, a short femur,
and a hyperechoic bowel were also associated with Down
syndrome, although the association with a short femur was
of borderline significance (Table 3). A short humerus was
not significantly associated with Down syndrome.
When maternal age, race, and associated sonographic
markers were combined in a multivariable model, maternal
race, a short femur, and a dilated renal pelvis were excluded
from the final prediction model due to nonsignificance. The
interaction between nuchal fold thickness and any major
abnormalities was found to be significant. The parameter
estimates of the final model are displayed in Table 4.
Using the parameter estimates in Table 4, the following formula was generated to calculate a woman’s adjusted
risk of carrying a fetus with Down syndrome: probability of
having a fetus with Down syndrome = 1 – {1/(1 + exp(–
9.05 + [0.1 × maternal age] + [3.8 × nuchal fold thickness
≥6 mm] + [3.6 × hyperechoic bowel] + [3.4 × any major
abnormalities] + [–2.2 × nuchal fold thickness ≥6 mm ×
any major abnormalities])}.
Among those seen from 2003 through 2006, there
were 673 women with abnormal serum screening results,
of which 31 fetuses with Down syndrome were detected
(4.6%). The mean maternal ages were 35.3 ± 6.0 years for
women with Down syndrome–affected fetuses and 30.9 ±
5.9 years for women without Down syndrome–affected fetuses. The mean gestational age at sonography for this cohort was 19.4 ± 1.7 weeks. When using this population for
validation of the two methods of risk adjustment, the use of
likelihood ratios had an area under the receiver operating
characteristic curve of 0.90 for Down syndrome detection,
whereas the use of logistic regression coefficients had an
area under the curve of 0.86 (Figure 1). Adopting a risk
cutoff point of 1/270, the sensitivity of the use of likelihood
ratios was 77.4% (95% CI, 58.9%–90.4) with a false-positive rate of 17.9% (95% CI, 15.0%–21.1%), whereas the
sensitivity of the use of logistic regression coefficients was
93.5% (95% CI, 78.6%–99.2%) with a false-positive rate
of 34.6% (95% CI, 30.9%–38.4%). There was a significant
difference in the screening efficiency between the two
methods for Down syndrome detection (positive results
by both methods, 106; negative results by both methods,
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389; positive results by likelihood ratios and negative results by logistic regression, 106; positive results by logistic
regression and negative results by likelihood ratios, 33;
exact McNemar χ2, P < .001). The agreement between the
two methods was fair (κ = 0.38; SE = 0.04; agreement,
73.6%; expected agreement, 57.5%).

Discussion
We compared the diagnostic accuracy of using likelihood
ratios versus logistic regression coefficients for Down syndrome screening at 15 to 22 weeks in a high-risk population. With a risk cutoff point of 1/270, there was a
significant difference in the screening efficiency for Down
syndrome between the two methods. Using likelihood ratios had a lower false-positive rate but also a lower detection rate, whereas using logistic regression coefficients had
a higher detection rate but a higher false-positive rate.
Likelihood ratios of sonographic markers have been
developed to modify a priori baseline risk estimates using
the Bayes theorem. Prior risk is based on either the maternal age risk or second-trimester serum screening risk.
Several authors have calculated likelihood ratios for sonographic markers.5–8 DeVore8 examined cardiovascular and
noncardiovascular prenatal sonographic markers and
used logistic regression to identify which combination of
markers significantly contributed to the identification
of fetuses with Down syndrome. In that study, the likelihood ratio for each significant marker was computed
from the logarithmic transformation of the corresponding coefficient. The study considered varying skills of the
physicians for diagnosing cardiovascular anomalies and examined models of different combinations, including using
both cardiovascular and noncardiovascular markers, using
noncardiovascular markers only, and using selective realtime sonography markers. That approach allowed the
physicians to choose makers according to their diagnostic
skills. Using the computing strategy described in that study,

physicians can compute the risk for Down syndrome on
the basis of the sonographic results. That is a very useful
study, providing likelihood ratios for positive and negative
findings on a second-trimester anomaly scan. However,
the study did not provide likelihood ratios for some of
the markers included in our study, such as an echogenic
intracardiac focus, a short femur, and a short humerus;
therefore, we were unable to use their data as reference.8
However, in this study, we used a similar approach as
DeVore’s study8 for computing likelihood ratios and individual risk factors for Down syndrome.
On the other hand, Nyberg et al5 calculated overall
and isolated likelihood ratios for 6 sonographic markers of
Down syndrome (nuchal fold thickness, a hyperechoic
bowel, a short humerus, a short femur, an echogenic intracardiac focus, and pyelectasis). Bromley et al6 further
evaluated the 6 markers with the addition of major structural anomalies. Finally, Nicolaides7 combined data from
the studies by Nyberg et al5 and Bromley et al6 and provided positive and negative likelihood ratios for sonographic makers of Down syndrome, which we used as
referential likelihood ratios for our study.
The findings from this study regarding the efficiency
of the likelihood ratio approach are similar to those from
other reports. For example, Nyberg et al9 also performed
an age-adjusted sonographic risk assessment for Down
syndrome, which multiplied a priori risk based on maternal age with likelihood ratios calculated on the basis of
the presence or absence of specific sonographic findings
for each patient. Using an age-adjusted sonographic risk
assessment and a threshold of 1/200, they reported sensitivity of 74% at a false-positive rate of 14.7%. Bahado-Singh
et al10 developed a comprehensive midtrimester test based
on multiple urine, serum, and sonographic markers and
used a multivariable gaussian algorithm plus age to derive
the patient-specific Down syndrome risk. The comprehensive midtrimester test finally consisted of the urine
human chorionic gonadotropin level, β-core fragment, and

Table 3. Associations Between Sonographic Markers and Down Syndrome in the Population From 1990 Through 2002
Characteristic
Patients
Nuchal fold thickness ≥6 mm
Hyperechoic bowel
Short femur
Short humerus
Echogenic intracardiac focus
Renal pelvis
Any major abnormalities

Down Syndrome
46 (2.5)
11 (23.9)
3 (6.5)
3 (6.7)
4 (11.1)
9 (19.6)
11 (23.9)
15 (32.6)

Non–Down Syndrome
1788 (97.5)
18 (1.0)
6 (0.3)
37 (2.1)
95 (6.4)
55 (3.1)
24 (1.3)
35 (2.0)

Unadjusted OR (95% CI)
30.9 (13.6–70.3)
20.7 (5.0–85.5)
3.3 (1.0–11.0)
1.8 (0.6–5.3)
7.7 (3.5–16.7)
23.1 (10.5–50.8)
24.2 (12.0–48.9)

P
<.001
<.001
.057
.258
<.001
<.001
<.001

Data are number (percent). CI indicates confidence interval; and OR, odds ratio.
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nuchal fold thickness and showed sensitivity of 93.7% at a
5% false-positive rate for the overall population. In the
validation population of our study, the use of likelihood
ratios generated sensitivity of 87.1% (95% CI, 70.2%–
96.4%) with a false-positive rate of 36.5% (95% CI, 32.7%–
40.3%) with a risk cutoff point of 1/270. The difference in
diagnostic accuracy between studies may result from different study populations, different likelihood ratios used,
different approaches to calculating the likelihood ratios,
and different cutoff points used to define a screen-positive
case. In this study, we used a cutoff of 1/270, which is the
risk for Down syndrome for a 35-year-old woman that has
been used in several previously published studies. The high
false-positive rate for our population suggests that a higher
cutoff may be preferable. A higher rate, however, would result in lower sensitivity. Thus, standardization is needed to
improve the performance of screening.
The approach of refining risk by multiplying sonographic likelihood ratios is based on the assumption that
there is no significant correlation between sonographic and
serum markers. Some authors argue that such assumptions
are not always accurate because different screening findings are not necessarily independent.3,7,8 Therefore, the use
of logistic regression coefficients from a predictive formula
has been proposed to facilitate an accurate understanding
of prenatal Down syndrome risk. DeVore8 examined noncardiac markers (including central nervous system malformations, choroid plexus cysts, nuchal translucency, a
hyperechoic bowel, and pyelectasis) and cardiac markers
(including ventricular septal defects, right-to-left chamber
disproportion, pericardial effusion, and outflow tract abnormalities). In that study, all but 3 markers (choroid
plexus cysts, mitral regurgitation, and outflow tract abnormalities) contributed significantly to the identification of
91% of fetuses with Down syndrome, with a false-positive
rate of 14%. The logistic coefficients were 4.2 for nuchal
fold thickness, 1.7 for a hyperechoic bowel, and 1.5 for pyelectasis. Interactions were found between nuchal fold

thickness and right-to-left chamber disproportion, with coefficients of –3.5. When only noncardiovascular markers
were examined, all markers but choroid plexus cysts contributed to the identification of 60% of fetuses with Down
syndrome, with a false-positive rate of 5.9%. Schluter and
Pritchard3 generated a formula based on multivariable
analysis of sonographic markers that adjusted the maternal age– and gestational age–derived risk for Down syndrome in a prospective group of unselected pregnant
women. They found that a thickened nuchal fold, a short
humerus, an echogenic bowel, renal pelvic dilatation, and
aneuploidy-associated anomalies were significantly associated with Down syndrome. They also found an interaction between gestational age and a thickened nuchal fold
thickness and between a short humerus and aneuploidyassociated anomalies. They suggested that risk estimates
should be derived from appropriate multivariable models
because of the relationship between sonographic findings.
Vergani et al4 developed a multivariable sonographic
model adjusted for gestational and maternal age in a population at high risk because of a maternal age of 35 years or
older. They found a nuchal fold thickness of 5 mm or
greater, renal pelvic dilatation, absence of a mid phalanx of
the fifth digit, noncardiac malformations, and isolated heart
defects to be significantly associated with Down syndrome,
with coefficients of 15.2, 2.9, 3.4, 3.0, and 4.1, respectively.
They also found a significant interaction between gestational age and nuchal fold thickness of 5 mm or greater and
heart defects, with coefficients of –0.80 and –3.6, respectively. With the exception of maternal age, which was used
as a categorical variable in that study, the coefficients for
the other markers were similar to those reported in our
study. Using this model and a risk cutoff point of 1/270,
they reported sensitivity of 83.3% with a false-positive rate
of 28.5% in their validation population. In our final parsimonious model, nuchal fold thickness of 6 mm or greater,
a hyperechoic bowel, an echogenic intracardiac focus, and
major abnormalities were associated with Down syn-

Table 4. Parameter Estimates for the Formula Generated for the Population From 1990 Through 2002

Characteristic
Maternal age
Nuchal fold thickness ≥6 mm
Hyperechoic bowel
Echogenic intracardiac focus
Any major abnormalities
Any major abnormalities × nuchal fold thickness ≥6 mm

Logistic Regression
Parameter Estimate
β
SE
0.1
3.8
3.6
2.2
3.1
–2.2

0.04
0.51
0.87
0.49
0.44
1.17

Adjusted OR (95% CI)
1.1 (1.1–1.2)
44 (16.0–121.3)
35.4 (6.4–196.7)
8.6 (3.3–22.7)
22.4 (9.4–53.6)
0.1 (0.01–1.1)

CI indicates confidence interval; and OR, odds ratio.
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Figure 1. Comparison of the areas under the receiver operating characteristic curve (AUC) between the use of likelihood ratios (LRs) and
the logistic regression coefficients in the population from 2003 through
2006. The use of likelihood ratios showed an area under the curve of
0.902, whereas the use of logistic regression coefficients showed an
area under the curve of 0.8653.

drome, with coefficients of 3.8, 3.6, 2.2, and 3.1, respectively. We found a significant interaction between nuchal
fold thickness of 6 mm or greater and major structural abnormalities, with a coefficient of –2.2. This finding was similar to DeVore’s finding of a significant interaction between
an increased nuchal skin fold and cardiac malformations.8
With a risk cutoff point of 1/270, the sensitivity of
using logistic regression coefficients was higher than that
reported by DeVore8 and Vergani et al4 (93.5%), but the
false-positive rate was also higher (34.6%). Moreover, a
comparison of the screening efficiency showed a significant difference between the use of likelihood ratios versus
logistic regression coefficients. Among the 4 studies using
the logistic regression approach, the sonographic markers
in the final models and the coefficients included in the final
equations were different. The studies by DeVore8 and Vergani et al4 and our study used high-risk populations,
whereas Schluter and Pritchard3 used an unselected population. All of these results suggest that the formulas from
multivariable logistic models vary between different populations and different centers.
Our study was not without limitations. For example,
recent data suggest that second-trimester nasal bone absence or hypoplasia has the potential to improve Down
syndrome detection. Cicero et al11 reported that the likelihood ratios of a hypoplastic nasal bone for Down syndrome were 132.1 (95% CI, 49.1–351.9) for white patients
and 8.5 (95% CI, 2.7–20.1) for African Caribbean patients,
and the respective values for a present nasal bone were 0.39
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(95% CI, 0.24–0.58) and 0.27 (95% CI, 0.05–0.77).
Odibo et al12 reported that combining the nasal bone with
other proven markers for Down syndrome (nuchal fold
thickness, femur and humerus lengths, choroid plexus
cysts, and an echogenic bowel) increased the sensitivity
from 59% to 82% and the specificity from 74% to 87%. In
another study,13 they showed that absence of a nasal bone
was a more efficient marker of Down syndrome than
nuchal fold thickness of greater than 6 mm. In our study,
we did not incorporate the nasal bone into our models because this marker was only introduced routinely into our
practice in recent years and would have limited our sample
size. However, we hope that future studies incorporating
the nasal bone and other second-trimester sonographic
markers of fetal aneuploidy would improve Down syndrome detection and decrease false-positive rates using either approach.
In our study, we included major abnormalities as a single variable and did not classify them into detailed subtypes, which may have overestimated the contribution of
this marker to our models or missed the associations between specific subtypes and Down syndrome. However,
we expect the impact of this limitation on our results to
have been small because the Down syndrome detection
rates of specific subtypes of major abnormalities (apart
from cardiac) are small.4,5 Previous studies also included
all of the subtypes as a single variable.4,5
Finally, as the use of first-trimester screening for Down
syndrome increases, its influence on second-trimester assessment of Down syndrome will become increasingly
important.14 Our study could not address the impact of
first-trimester screening on the performance of genetic
sonography because of a similar limitation as for the nasal
bone mentioned above. In addition, because of the relatively large number of variables associated with Down syndrome and the small number of Down syndrome cases,
our study may not have had enough power to detect small
but possibly important differences in screening efficiency
between the use of likelihood ratios and logistic regression coefficients. Therefore, our failure to show a significant difference between the two methods does not equate
to the likelihood ratio method’s being superior to the logistic regression method.
Finally, our study may be criticized for using published
likelihood ratios for one set of comparisons and using coeffeicients derived from our population for the logistic
regression approach. We chose to use the published likelihood ratios because they came from 2 robust data sets.5,6
Although it would have been attractive to use only data
from our center for comparing both methods, the ap-
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proach would have limited the generalizability of the findings to other populations.
In conclusion, we found a significant difference in diagnostic accuracy for Down syndrome between the use of
likelihood ratios and logistic regression coefficients. The
use of likelihood ratios resulted in a lower false-positive
rate but also a lower detection rate, whereas the use of logistic regression coefficients resulted in a higher detection rate but also a higher false-positive rate. Given the
ease of using the likelihood ratio method and the familiarity of clinicians with that approach, the findings suggest that the continuing use of the likelihood ratio
approach is reasonable, especially when the goal is to reduce the false-positive rate. Our results indicate that future studies on the genetic sonogram should aim to
identify variables that could result in improvement in diagnostic accuracy, and standardization of markers included in such studies is desirable.

11. Cicero S, Sonek JD, McKenna DS, Croom CS, Johnson L, Nicolaides
KH. Nasal bone hypoplasia in trisomy 21 at 15–22 weeks’ gestation. Ultrasound Obstet Gynecol 2003; 21:15–18.
12. Odibo AO, Sehdev HM, Sproat L, et al. Evaluating the efficiency of using
second-trimester nasal bone hypoplasia as a single or a combined marker
for fetal aneuploidy. J Ultrasound Med 2006; 25:437–441.
13. Odibo AO, Sehdev HM, Gerkowicz S, Stamilio DM, Macones GA.
Comparison of the efficiency of second-trimester nasal bone hypoplasia
and increased nuchal fold in Down syndrome screening. Am J Obstet Gynecol 2008; 199:281.e1–281.e5.
14. Aagaard-Tillery KM, Malone FD, Nyberg DA, et al. Role of secondtrimester genetic sonography after Down syndrome screening. Obstet Gynecol 2009; 114:1189–1196.
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